Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25347760 | 1.00 | GSK3B (0.41) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25346885 | 1.00 | GSK3B (0.41) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL29513909 | 1.00 | GSK3B (0.41) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25346177 | 0.93 | GSK3B (0.40) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25348105 | 0.93 | GSK3B (0.40) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25346181 | 0.93 | GSK3B (0.40) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25347720 | 0.89 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL25347724 | 0.89 | MAP4K1 (0.46) | MAP4K1 | |
| SCHEMBL25347848 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14FGFR4ABL1 | |
| SCHEMBL25346743 | 0.87 | MAP4K1 (0.44) | GSK3BGSK3AMAPK14FGFR4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2024-02-08 | — | — | US | disclosed |
| EP-4225741-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | Enliven Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043420-A1 | 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | GSK3B 669/4885GSK3A 670/4885MAPK14 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.